Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pacific Biosciences ( (PACB) ) has provided an update.
Pacific Biosciences announced amendments to the change in control and severance agreements for its CEO, Christian O. Henry, and COO, Mark Van Oene. These changes include lump sum severance payments and an extension of the change of control period, reflecting the company’s commitment to secure executive leadership stability amid potential transitions.
More about Pacific Biosciences
Pacific Biosciences of California, Inc. operates in the biotechnology industry, focusing on providing advanced sequencing technologies and solutions to support scientific research and clinical applications.
YTD Price Performance: -79.15%
Average Trading Volume: 9,696,472
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $560.1M
Learn more about PACB stock on TipRanks’ Stock Analysis page.
